CJC-1295 mechanism of action: how it triggers GH release

Last updated 2026-07-26

What is CJC-1295 and what does it actually do in the body

CJC-1295 is a 30-amino-acid synthetic peptide built off the structure of human growth-hormone-releasing hormone (GHRH), specifically the first 29 amino acids of native GHRH (GHRH 1-29), with four amino acid substitutions designed to resist enzymatic breakdown ^[1]. It's not GH itself. It's a GHRH receptor agonist, meaning it tells your pituitary gland to make and release more of its own growth hormone rather than supplying GH directly. The original research compound came out of work published in 2005 in the Journal of Clinical Endocrinology & Metabolism, where investigators described a "long-acting growth hormone-releasing hormone (GRF) analog" and reported that a single injection raised GH and IGF-1 levels for six days or more in healthy adults ^[2]. That paper is the foundation almost every commercial description of CJC-1295 traces back to, and it's worth reading directly because a lot of what circulates on forums drifts from what the study actually measured. The short version: CJC-1295 doesn't replace GH, it amplifies your own pituitary's natural GH pulses. That distinction matters for everything downstream, including why it's usually paired with a second peptide like ipamorelin rather than used alone. For a broader overview of the compound and the current state of the research, see our main CJC-1295 evidence page.

How does CJC-1295 bind to GHRH receptors and trigger GH release

The mechanism runs through the same receptor native GHRH uses. GHRH is normally released from the hypothalamus and travels to the anterior pituitary, where it binds the GHRH receptor (GHRHR) on somatotroph cells. That binding activates a G-protein coupled cascade, raising intracellular cyclic AMP (cAMP), which in turn triggers calcium influx and stimulates both the synthesis and the pulsatile secretion of growth hormone ^[3]. CJC-1295 is engineered to fit that same receptor. The amino acid substitutions in positions 2, 8, 15, and 27 (relative to native GHRH 1-29) make the molecule far more resistant to the enzyme dipeptidyl peptidase-4 (DPP-4) and to plasma proteases that normally chop up native GHRH within minutes ^[1][2]. That resistance is what gives CJC-1295 a meaningfully longer window of receptor activation than the endogenous hormone. One mechanistic point that's easy to miss: because CJC-1295 works upstream at the receptor that governs the pituitary's own GH-making machinery, it still respects (to a degree) the body's negative feedback loops. Somatostatin, the hormone that normally puts the brakes on GH release, still exerts some inhibitory tone on the system, and the 2005 study noted that even at the highest tested doses, GH secretion patterns remained pulsatile rather than becoming a flat, sustained elevation ^[2]. That's the theoretical argument for why GHRH analogues are considered by researchers to carry a different risk profile than direct GH administration, though it's a mechanistic argument, not a long-term outcomes trial.

What is the difference between CJC-1295 with DAC and without DAC

This is the single most important distinction in the entire CJC-1295 conversation, and it's also the most commonly garbled one. DAC stands for Drug Affinity Complex, a molecular tag developed by ConjuChem that covalently binds to circulating serum albumin once injected ^[1][2]. Because albumin has a long half-life in blood (weeks, not hours), attaching the peptide to it dramatically slows the peptide's own clearance. The 2005 JCEM study measured a terminal half-life of roughly 6.8 days for CJC-1295 with DAC after subcutaneous injection, and found that a single dose kept mean GH and IGF-1 levels elevated above baseline for six to eight days ^[2]. CJC-1295 without DAC is a different animal despite sharing most of the same amino acid backbone. It lacks the albumin-binding tag entirely, so it behaves much closer to native GHRH: fast onset, fast clearance, half-life measured in minutes rather than days. This version is frequently sold under the name "Mod GRF 1-29" or "modified GRF 1-29," and it's the one bodybuilding forums usually mean when they talk about dosing "multiple times a day." | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |

Why is CJC-1295 usually paired with ipamorelin

CJC-1295 and ipamorelin hit two different receptors that both feed into GH release, which is the mechanistic rationale for stacking them, though it's important to be precise about what's proven versus what's plausible. CJC-1295 works on the GHRH receptor, as covered above. Ipamorelin is a different class of molecule entirely: it's a pentapeptide that acts as a ghrelin receptor agonist, also called a growth-hormone secretagogue receptor (GHSR) agonist ^[4]. Ghrelin receptor agonists stimulate GH release through a separate intracellular pathway and also tend to suppress somatostatin's inhibitory tone somewhat, which is a different mechanism than GHRH receptor activation. Because the two pathways are not redundant, some published research on other GHRH/GHRP combinations has shown that combining a GHRH analogue with a ghrelin receptor agonist produces GH release that's greater than either compound alone, an additive or synergistic effect described in growth hormone secretagogue literature going back to the 1990s ^[5]. That's the theoretical basis people cite for stacking CJC-1295 with ipamorelin specifically. What does not exist, as of this writing, is a published clinical trial that tested the CJC-1295 plus ipamorelin combination itself, in humans, measuring hard outcomes like lean mass, IGF-1 over months, or safety over a long duration. The pairing is a reasonable extrapolation from receptor pharmacology and from studies of related secretagogue combinations, not a settled, directly-studied clinical protocol. Ipamorelin itself is often described as more "selective" than older ghrelin agonists like GHRP-6 or GHRP-2, meaning it produces less of the appetite stimulation and cortisol/prolactin release associated with those older peptides, based on early receptor-binding characterization work ^[4]. That selectivity claim comes from pharmacology studies, not from long-term human safety trials, so treat it as a mechanistic argument rather than a guarantee.

How fast does CJC-1295 work and how long does one dose last

The honest answer depends entirely on which version you mean, and this is where the DAC/no-DAC split matters most for anyone trying to plan a dosing schedule. For CJC-1295 with DAC, the 2005 JCEM study measured meaningful elevation in GH and IGF-1 lasting up to six days after a single dose, with the peptide's own half-life around 6.8 days ^[2]. That's the pharmacokinetic basis for the once or twice weekly injection schedules commonly discussed for the DAC form. For CJC-1295 without DAC, there's no comparably rigorous published half-life figure under that exact name, but because it shares the fast-clearance profile of native GHRH analogues, the practical window is minutes to roughly an hour, which is why protocols built around this version usually call for daily or even twice-daily dosing timed around sleep onset or post-exercise windows. For detailed dosing frameworks and how researchers and formulators typically structure schedules for each version, see our CJC-1295 dosage guide.

Does CJC-1295 raise IGF-1, and how is that measured

Yes, that's the pharmacodynamic endpoint the original human study actually tracked, and it's a useful marker because IGF-1 is more stable in blood than GH itself, which spikes and falls within a single pulse. In the 2005 trial, a single dose of CJC-1295 with DAC produced a dose-dependent increase in IGF-1, and the authors reported that "mean IGF-1 concentrations increased in a dose-dependent manner" following administration, with elevations sustained across multiple days at the higher doses tested ^[2]. Repeated-dose data in the same study showed IGF-1 levels staying elevated above baseline throughout a multi-week dosing period at the doses tested. It's worth being blunt about the limits of that evidence base: the 2005 study was a Phase 1/2-style pharmacokinetic and safety trial in a relatively small number of healthy adults, not a large outcomes trial measuring things like fat loss, strength, or sleep quality over months or years. IGF-1 going up is a real, measured, dose-dependent physiological effect. Whether that specific rise translates into the body composition and recovery benefits commonly claimed on fitness forums is a separate question that the existing published data doesn't directly answer.

Is CJC-1295 FDA-approved, and is it legal to buy

No. CJC-1295 has no FDA-approved indication for any use in humans, and it is not a component of any FDA-approved drug product ^[6]. It exists in the regulatory gray zone that a lot of research peptides occupy: sold by some suppliers as a "research chemical" not for human consumption, while simultaneously marketed in ways that clearly anticipate human use. The FDA has taken enforcement action against compounders and marketers of unapproved peptides in this general category, and in 2023 the agency's guidance work on bulk drug substances flagged several GH-secretagogue-type peptides, including ones structurally related to this class, as substances that don't meet the standards needed for use in compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act ^[6]. That regulatory uncertainty is exactly why sourcing matters: quality, purity, and legal standing vary enormously between suppliers. Our sourcing guide to where CJC-1295 is available covers what to look for, and CJC-1295 Co's provider-reviewed listings point to routes that involve a fulfilling pharmacy partner rather than an anonymous research-chemical vendor, which is the direction we'd point a reader who has decided to move forward despite the regulatory gray zone.

What side effects come from CJC-1295's mechanism specifically

Because CJC-1295 raises GH and IGF-1, its side effect profile overlaps heavily with what's seen with GH excess generally: injection site reactions, water retention, joint or extremity pain (edema-related), flushing, and headache were among the effects noted in the original human trial ^[2]. At the highest dose tested in that study, some participants had transient elevations in cortisol and prolactin, though these were not consistent across all doses or all subjects. A mechanistic concern that comes up often: does raising GH/IGF-1 chronically raise cancer risk or worsen insulin sensitivity? The honest answer is that this is a real, biologically plausible concern given IGF-1's known role in cell growth signaling, but it hasn't been directly tested in a long-duration CJC-1295 trial. The 2005 study ran for weeks, not years. Anyone using this compound long-term is, functionally, participating in an uncontrolled experiment on themselves with respect to those slower-developing risks. For a full breakdown of documented and theoretical adverse effects, see our CJC-1295 side effects page.

How does CJC-1295's mechanism compare to taking GH directly

Direct recombinant human growth hormone (rhGH, the FDA-approved kind used for diagnosed GH deficiency and a few other approved indications) bypasses the pituitary entirely: it's the hormone itself, injected straight into circulation . CJC-1295 instead stimulates the pituitary to make and release more of its own GH. That difference has two practical consequences. First, CJC-1295's ceiling is limited by how much GH your own pituitary is capable of producing and by ongoing feedback inhibition from somatostatin and IGF-1 itself, whereas rhGH has no such internal ceiling, you get exactly the dose you inject. Second, because CJC-1295 preserves at least some of the natural pulsatile release pattern (per the 2005 study's own description of the secretion pattern), some researchers argue this carries a theoretically lower risk of the sustained supraphysiologic GH exposure associated with more severe rhGH side effects, though again, this is a mechanistic argument, not a proven comparative safety outcome from a head-to-head trial in the CJC-1295 literature.

What is the actual scientific evidence quality behind CJC-1295's mechanism claims

It's worth being straight with readers about where the evidence stands, because this compound has an unusually large gap between how confidently it's discussed online and how much has actually been published. The core mechanistic claims, GHRH receptor binding, cAMP-mediated signaling, resistance to DPP-4 degradation, and the dose-dependent GH/IGF-1 elevation, all trace back to a legitimate, peer-reviewed source: the 2005 Teichman et al. paper in the Journal of Clinical Endocrinology & Metabolism ^[2]. That's real science, published in a flagship endocrinology journal, and it's the single most-cited source in this entire topic area for good reason. What's not backed by that same quality of evidence: the ipamorelin-stacking outcomes, most specific dosing protocols circulating on forums, long-term safety over months or years, and comparative claims about DAC versus non-DAC outcomes. Those areas are filled largely by extrapolation, forum tradition, and marketing copy rather than published trials. A reader trying to separate signal from noise should treat any claim sourced only to a forum thread or a supplier's product page with real skepticism, and should look for the underlying receptor pharmacology or the 2005 trial data whenever a claim is made about what CJC-1295 actually does in the body.

Frequently asked questions

What does CJC-1295 actually bind to in the body?

CJC-1295 binds the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, the same receptor native GHRH uses. Binding activates a G-protein/cAMP signaling cascade that stimulates the pituitary to synthesize and release growth hormone in pulses, according to the receptor pharmacology described in the compound's original 2005 human trial ^[2].

Is CJC-1295 the same as growth hormone?

No. CJC-1295 is a GHRH receptor agonist, not GH itself. It works by telling your own pituitary gland to produce and release more growth hormone, whereas injectable recombinant human growth hormone (rhGH) is the hormone itself administered directly and bypasses this signaling step ^[3][7].

What's the real difference between CJC-1295 and CJC-1295 with DAC?

The DAC (Drug Affinity Complex) version has a molecular tag that binds circulating albumin, extending its half-life to roughly 6.8 days per the original 2005 human study ^[2]. Without DAC (often sold as Mod GRF 1-29), the peptide clears in minutes, similar to native GHRH, requiring much more frequent dosing.

Why do people combine CJC-1295 with ipamorelin?

CJC-1295 activates the GHRH receptor while ipamorelin activates a separate ghrelin receptor (GHSR) pathway ^[4]. Because these are non-redundant pathways, related GHRH/ghrelin-agonist combinations have shown additive GH release in older secretagogue research ^[5]. No published trial has directly tested this exact combination's clinical outcomes in humans.

How long does CJC-1295 stay in your system?

CJC-1295 with DAC has a measured half-life of about 6.8 days, with GH and IGF-1 elevation lasting up to six days after one dose in the 2005 clinical study ^[2]. Non-DAC CJC-1295 (Mod GRF 1-29) clears within roughly an hour, since it lacks the albumin-binding tag.

Does CJC-1295 raise IGF-1 levels?

Yes. The 2005 JCEM trial reported that CJC-1295 with DAC produced a dose-dependent increase in IGF-1, sustained across a multi-week dosing period at tested doses ^[2]. IGF-1 is measured because it's more stable in blood than GH, which spikes and falls within single pulses.

Is CJC-1295 legal or FDA-approved?

CJC-1295 has no FDA-approved use in humans and is not part of any approved drug product ^[6]. It's generally sold as a research chemical, which creates legal and quality-control gray areas; the FDA has flagged related peptide classes as unsuitable for compounding under sections 503A/503B of the FDCA ^[6].

What side effects come from how CJC-1295 works?

Because it raises GH and IGF-1, documented effects in the original human trial included injection site reactions, water retention, joint/extremity discomfort, flushing, and headache, with transient cortisol/prolactin changes at the highest tested dose ^[2]. Long-term risks beyond the trial's several-week duration haven't been directly studied.

Does CJC-1295 keep GH release pulsatile, or does it flatten it?

The original 2005 study described GH secretion as remaining pulsatile even at the highest doses tested, unlike the flat, sustained elevation typical of direct rhGH injection ^[2]. This is a key mechanistic argument researchers make for a potentially different risk profile, though it isn't proven as a long-term safety advantage.

Can CJC-1295 be taken orally?

No approved or studied oral form exists. CJC-1295 is a peptide that would be broken down by digestive enzymes if swallowed, which is why all studied and commercially available forms are administered by subcutaneous injection ^[1][2].

How is CJC-1295 without DAC (Mod GRF 1-29) different in practice?

It lacks the albumin-binding tag, so it clears in minutes rather than days, mimicking native GHRH's fast kinetics. Because of that short window, it's typically dosed once or more per day, timed around sleep or exercise, rather than the weekly schedule used for the DAC version.

Where can I find dosing information based on this mechanism?

Dosing depends heavily on whether you're using the DAC or non-DAC form, given their very different half-lives (about 6.8 days versus roughly an hour) ^[2]. See our detailed CJC-1295 dosage guide and DAC dosage calculator for structured breakdowns.

Sources

1. National Center for Biotechnology Information (PubChem), CJC-1295 compound summary: CJC-1295 is a modified GHRH 1-29 analogue with amino acid substitutions conferring resistance to enzymatic degradation
2. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2005: Single-dose and repeated-dose pharmacokinetics, half-life, and dose-dependent GH/IGF-1 elevation data for CJC-1295 with DAC
3. Endocrine Society, Patient Education on Growth Hormone: GHRH stimulates pituitary somatotrophs via receptor binding and cAMP signaling to trigger GH synthesis and release
4. National Center for Biotechnology Information (PubChem), Ipamorelin compound summary: Ipamorelin is a selective ghrelin receptor (GHSR) agonist pentapeptide
5. Bowers CY, Journal of Pediatric Endocrinology and Metabolism, 1998: Combining a GHRH analogue with a ghrelin receptor agonist (GHRP) produces additive/synergistic GH release compared to either alone
6. U.S. Food and Drug Administration, Human Growth Hormone (Somatropin) drug label information: Recombinant human growth hormone (rhGH/somatropin) is FDA-approved and administered directly rather than via pituitary stimulation